OTC Product Roundup: Digestive Health

Stephanie Sober, MD, MSHP, investigator on the pivotal research that supported the prescription-to-OTC switch of Opill, shares insights on how the medicine is reshaping the reproductive landscape.

Ragweed season begins in late August and can run through early November.

The approval offers a first of its kind treatment option for patients living with nonerosive GERD.

Ustekinumab-ttwe, a biosimilar to ustekinumab (Stelara) is expected launch in the US in February 2025.

McKesson’s private brand of OTC health and wellness products are a great way for independent pharmacies to increase profits.

Study results were promising, but larger studies are needed.